These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 25040585

  • 1. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M.
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [Abstract] [Full Text] [Related]

  • 2. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen.
    Kamar N, Del Bello A, Congy-Jolivet N, Guilbeau-Frugier C, Cardeau-Desangles I, Fort M, Esposito L, Guitard J, Gamé X, Rostaing L.
    Clin Transplant; 2013 Sep; 27(3):455-62. PubMed ID: 23621682
    [Abstract] [Full Text] [Related]

  • 3. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 4. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y, Ramon D, Luan FL, Sung R, Samaniego M.
    Clin Transpl; 2012 Dec; ():247-56. PubMed ID: 23721029
    [Abstract] [Full Text] [Related]

  • 5. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 6. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C, Mangus R, Saxena R, Lobashevsky A, Higgins N, Fridell J, Tector AJ.
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [Abstract] [Full Text] [Related]

  • 7. Influenza vaccination and humoral alloimmunity in solid organ transplant recipients.
    Vermeiren P, Aubert V, Sugamele R, Aubert JD, Venetz JP, Meylan P, Pascual M, Manuel O.
    Transpl Int; 2014 Sep; 27(9):903-8. PubMed ID: 24797932
    [Abstract] [Full Text] [Related]

  • 8. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM, Everly MJ, Haisch CE, Ozawa M, Briley KP, Parker K, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC.
    Clin Transpl; 2011 Sep; ():337-40. PubMed ID: 22755428
    [Abstract] [Full Text] [Related]

  • 9. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Sep; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 10. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY, Kaneku H, Farmer DG.
    Clin Transpl; 2014 Sep; ():153-9. PubMed ID: 26281140
    [Abstract] [Full Text] [Related]

  • 11. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.
    Croze LE, Tetaz R, Roustit M, Malvezzi P, Janbon B, Jouve T, Pinel N, Masson D, Quesada JL, Bayle F, Zaoui P.
    Transpl Int; 2014 Aug; 27(8):775-83. PubMed ID: 24684741
    [Abstract] [Full Text] [Related]

  • 12. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M, Carroll RP, Tsiopelas E, Clayton P, Coates PT.
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [Abstract] [Full Text] [Related]

  • 13. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
    Everly MJ.
    Clin Transpl; 2011 Jul; ():319-25. PubMed ID: 22755425
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE, Gralla J, Chan L, Wiseman AC.
    Clin Transpl; 2011 Jul; ():359-64. PubMed ID: 22755431
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, Boletis JN.
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [Abstract] [Full Text] [Related]

  • 16. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [Abstract] [Full Text] [Related]

  • 17. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X, Ishida H, Yamaguchi Y, Tanabe K.
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [Abstract] [Full Text] [Related]

  • 18. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S, Watarai Y, Goto N, Hiramitsu T, Tsujita M, Okada M, Futamura K, Tomosugi T, Nishihira M, Sakamoto S, Kobayashi T.
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [Abstract] [Full Text] [Related]

  • 19. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA.
    Clin Transpl; 2011 Jun; ():351-8. PubMed ID: 22755430
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.